Ingenuity Systems and TransMed Systems said this week that they will integrate their software products in order to support research efforts focused on identifying the links between genes and drug response.
Under the terms of the agreement, TransMed, a life sciences application and services company headquartered in Cupertino, Calif., will integrate its XB Bio-Integration Suite with Ingenuity Pathway Analysis.
The combined platform will enable joint customers to collect and analyze pre-clinical and clinical data in the context of signaling and metabolic pathways, networks, and cellular processes that are available in IPA.
Doug Bassett, Ingenuity's chief scientific officer and chief technology officer, said in a statement that researchers will be able to "link genotypes to phenotypes, identify potential biomarkers, generate hypotheses, and understand the molecular differences between patient populations," which will result in "improved diagnostics and therapeutics."
Further details about the companies' integration plans were not disclosed.
TransMed's XB Bio-Integration Suite is a data analytics and management tool that lets users capture, analyze, visualize, and share their genomic data. The tool lets users access multiple genomic data sources, create patient cohorts, and generate hypotheses.
Included in the suite is a Personalized Medicine Module, offered as an add-on, that leverages multiple algorithms to create personalized medicine reports that correlate molecular disease characteristics with potential drug therapies.